Verteporfin photodynamic therapy retreatment of normal retina and choroid in the cynomolgus monkey

Ophthalmology

Volumn 106, Issue 10, 1999, Pages 1915-1923

  Reinke, Martin H ^a   Canakis, Christina ^a   Husain, Deeba ^a   Michaud, Norman ^b   Flotte, Thomas J ^b   Gragoudas, Evangelos S ^a   Miller, Joan W ^a,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c MASSACHUSETTS EYE AND EAR INFIRMARY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOPORPHYRIN DERIVATIVE; LIPOSOME; PHOTOSENSITIZING AGENT; PORPHYRIN;

ANIMAL; ARTICLE; CHEMICALLY INDUCED DISORDER; CHOROID; CHOROID DISEASE; DRUG EFFECT; EYE FUNDUS; FLUORESCENCE ANGIOGRAPHY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MACACA; OPTIC DISK; OPTIC NERVE; OPTIC NERVE DISEASE; PATHOLOGY; PHOTOCHEMOTHERAPY; PHOTOGRAPHY; RETINA; RETINA DISEASE; RETREATMENT; SAFETY;

ANIMALS; CHOROID; CHOROID DISEASES; FLUORESCEIN ANGIOGRAPHY; FUNDUS OCULI; HUMANS; INFUSIONS, INTRAVENOUS; LIPOSOMES; MACACA FASCICULARIS; OPTIC DISK; OPTIC NERVE; OPTIC NERVE DISEASES; PHOTOCHEMOTHERAPY; PHOTOGRAPHY; PHOTOSENSITIZING AGENTS; PORPHYRINS; RETINA; RETINAL DISEASES; RETREATMENT; SAFETY;

EID: 0033208744     PISSN: 01616420     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0161-6420(99)90401-3     Document Type: Article

References (24)

1. Klein R, Klein BEK, Linton KLP. Prevalence of age-related maculopathy. The Beaver Dam Eye Study. Ophthalmology 1992;99:933-43.
2. Ferris FL III, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol 1984;102:1640-2.
3. Risk factors for neovascular age-related macular degeneration. The Eye Disease Case-Control Study Group. Arch Ophthalmol 1992;110:1701-8.
4. Bressler NM, Bressler SB, Gragoudas ES. Clinical characteristics of choroidal neovascular membranes. Arch Ophthalmol 1987;105:209-13.
5. Recurrent choroidal neovascularization after argon laser photocoagulation for neovascular maculopathy. Macular Photocoagulation Study Group. Arch Ophthalmol 1986;104:503-12.
6. Argon laser photocoagulation for neovascular maculopathy. Three-year results from randomized clinical trials. Macular Photocoagulation Study Group. Arch Ophthalmol 1986;104: 694-701.
7. Persistent and recurrent neovascularization after laser photocoagulation for subfoveal choroidal neovascularization of age-related macular degeneration. Macular Photocoagulation Study Group. Arch Ophthalmol 1994;112:497-9.
8. Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. Macular Photocoagulation Study Group. Arch Ophthalmol 1991;109:1220-31.
9. Laser photocoagulation of subfoveal neovascular lesions of age-related macular degeneration. Updated findings from two clinical trials. Macular Photocoagulation Study Group. Arch Ophthalmol 1993;111:1200-9.
10. Argon laser photocoagulation for neovascular maculopathy. Five-year results from randomized clinical trials. Macular Photocoagulation Study Group. Arch Ophthalmol 1991;109: 1109-14.
11. Miller JW, Walsh AW, Kramer M, et al. Photodynamic therapy of experimental choroidal neovascularization using lipoprotein delivered benzoporphyrin. Arch Ophthalmol 1995; 113:810-8.
12. Kramer M, Miller JW, Michaud N, et al. Liposomal benzoporphyrin derivative verteporfin photodynamic therapy. Selective treatment of choroidal neovascularization in monkeys. Ophthalmology 1996;103:427-38.
13. Husain D, Miller JW, Michaud N, et al. Intravenous infusion of liposomal benzoporphyrin derivative for photodynamic therapy of experimental choroidal neovascularization. Arch Ophthalmol 1996;114:978-85.
14. Miller JW, Gragoudas, ES, Young LHY, inventors. Use of green porphyrins in ocular diagnosis and therapy. US patent 209,473. 1997.
15. Husain D, Miller JW, Kenney AG, et al. Photodynamic therapy and digital angiography of experimental iris neovascularization using liposomal benzoporphyrin derivative. Ophthalmology 1997;104:1242-50.
16. Miller JW, Schmidt-Erfurth U, Sickenberg M, et al. Photodynamic therapy for choroidal neovascularization due to age-related macular degeneration with verteporfin: results of a single treatment in a phase I and II study. Arch Ophthalmol 1999; in press.
17. Schmidt-Erfurth U, Miller JW, Sickenberg M, et al. Photodynamic therapy for choroidal neovascularization due to age-related macular degeneration with verteporfin: results of retreatments in a phase I and II study. Arch Ophthalmol 1999; in press.
18. Marshall J. Interactions between sensory cells, glial cells and the retinal pigment epithelium and their response to photocoagulation. Dev Ophthalmol 1981;2:308-17.
19. Smiddy WE, Fine SL, Quigley HA, et al. Cell proliferation after laser photocoagulation in primate retina. An autoradiographic study. Arch Ophthalmol 1986;104:1065-9.
20. Wallow IHL, Tso MOM. Repair after xenon arc photocoagulation. 3. An electron microscopic study of the evolution of retinal lesions in rhesus monkeys. Am J Ophthalmol 1973;75: 957-72.
21. Valentino TL, Kaplan HJ, Del Priore LV, et al. Retinal pigment epithelial repopulation in monkeys after submacular surgery. Arch Ophthalmol 1995;113:932-8.
22. Husain D, Kramer M, Kenney AG, et al. Effects of photodynamic therapy using verteporfin on experimental choroidal neovascularization and normal retina and choroid up to seven weeks after treatment. Invest Ophthalmol Vis Sci 1999; in press.
23. Heriot WJ, Machemer R. Pigment epithelial repair. Graefes Arch Clin Exp Ophthalmol 1992;230:91-100.
24. TAP Study Group. Verteporfin (Visudyne) therapy of subfoveal choroidal neovascularization in age-related macular degeneration. One year results of two randomized clinical trials. TAP Report #1. Arch Ophthalmol 1999; in press.